A new ELISA for dermatomyositis autoantibodies: Rapid introduction of autoantigen cDNA to recombinant assays for autoantibody measurement

Yoshinao Muro, Kazumitsu Sugiura, Masashi Akiyama

Research output: Contribution to journalReview article

20 Citations (Scopus)


Advances in immunology, biochemistry, and molecular biology have enabled the development of a number of assays for measuring autoantibodies. ELISA has been widely used, because it can deal with relatively large numbers of serum samples more quickly than other immunologic methods, such as immunoblotting and immunoprecipitation. Recombinant autoantigens, which are generally produced in E. coli using the relevant cloned cDNA, are necessary for ELISA. Conventional clinical ELISA tests are limited in their ability to purify proteins free of bacterial contaminants, and the process is labor intensive. We recently developed new ELISA tests that utilize simple in vitro transcription and translation labeling of autoantigens in order to measure dermatomyositis- (DM-) specific autoantibodies, including autoantibodies to Mi-2, MDA5, NXP-2, TIF1-α, and TIF1-γ. This method may allow for the rapid conversion of cDNAs to a chemiluminescent ELISA to detect autoantibodies that are found not only in DM but also in other autoimmune diseases.

Original languageEnglish
Article number856815
JournalClinical and Developmental Immunology
Publication statusPublished - 01-12-2013


All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this